This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Validity of estimate of costs
Only direct costs were included. Indirect costs related to lost productivity were not considered. Continued quality improvements in terms of post-operative recovery time and early discharge are likely to decrease hospital costs. Costs for management of late complications of surgery were not included. In order to be inclusive, the cost of any vascular treatment may need to be calculated over 2 or 3 years. Costs were derived from a local source, and are unlikely to be generalisable to other settings as no sensitivity analysis was performed on costs. The authors reported costs on the basis of cost per limb rather than cost per patient. This method of calculation may tend to skew cost data in favour of bypass grafts rather than angioplasty.
Other issues
Comparisons with other relevant studies were not made and the generalisability of the results to other settings or countries was not discussed. However, the authors do not appear to have presented their results selectively. The study enrolled patients with severe aortoiliac occlusive disease and this was reflected in the authors' conclusions.
Implications of the study
The gold standard for cost-effective treatment of severe aortoiliac occlusive disease remains direct surgical reconstruction. Future studies should compare direct surgical, indirect surgical, and non-operative endovascular treatment strategies.
Source of funding
None stated. 
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